Skip to content

What is a Schedule 14D-9?

What a Schedule 14D-9 is, who files it and why, when it's due, what's inside and a real example.

What it is

A Schedule 14D-9 is the target company's filing in answer to a tender offer. It says whether the board recommends tendering, and why.

Also called: SC 14D9, SC 14D9/A, SC14D9C, Solicitation/recommendation statement, The company's response

In plain words

Say a collector offers to buy a rare stamp from each member of a club. The club's committee can't accept for the members.

But it must tell them what it thinks. Take the offer, refuse it, or no view either way, and why.

A Schedule 14D-9 is that advice, from the target's board to its holders, filed with the SEC.

Who files it and why

Sometimes a buyer makes a tender offer. The target company usually answers it in a Schedule 14D-9. On EDGAR, the filing's code is SC 14D9.

Say Woodgrove offers $50.00 a share in cash for Litware. Woodgrove files its offer on a Schedule TO.

Litware files the Schedule 14D-9. It tells holders whether Litware's board recommends tendering, and why.

The rule behind it is Rule 14d-9. Others who urge holders to tender or not, such as a large holder, may have to file one too.Source 1

The buyer doesn't file one, since its Schedule TO covers it.Source 1

Before the offer starts, the target can file its written messages about the deal under the same cover, with a box checked. EDGAR codes these SC14D9C.Source 1

When it is due

Under Rule 14e-2, the target must tell holders its position within 10 business days of the offer's start, with its reasons.Source 2

Under Rule 14d-9, that statement goes on a Schedule 14D-9, even if the board stays neutral. It's filed as soon as practicable on the day it first goes out.Source 1

Until then, the target may send a short notice that only says the board is reviewing the offer. It asks holders to wait for its answer.

That answer must be promised by a set date, within 10 business days of the start. The rule calls this a stop-look-and-listen communication.Source 1

A notice limited to those points needs no Schedule 14D-9.Source 1

Under an SEC order of April 16, 2026, some agreed cash offers can stay open for just 10 business days.Source 3

One condition: the target files and sends its Schedule 14D-9 by 5:30 p.m. Eastern time on the first business day after the start.Source 3

If a material fact in the statement changes, the target must promptly file an amendment, coded SC 14D9/A, and tell holders. It's filed no later than the day the change first goes out.Source 1

What's inside, and where to look

The form has nine numbered items. The offer's price, conditions and end date sit in the buyer's Offer to Purchase, filed with its Schedule TO. The 14D-9 usually refers to them.Source 4

The main parts:

The recommendation
Item 4. Whether the board recommends accepting or rejecting the offer, with its reasons. A bare claim that the offer is in holders' best interests isn't enough.Source 4
Background of the offer
Usually in Item 4. The history of the talks: who approached whom, other possible buyers, and how the price moved.
Fairness opinions
Usually in Item 4, with the full text attached. A financial advisor gives the board its opinion. It says whether the price is fair to holders from a financial point of view.
Interests of directors and officers
Item 3. Agreements and conflicts of interest involving the target's insiders or the buyer. Cash-outs of equity awards are one example.Source 4
Golden parachute pay
Item 8. A table of each named executive officer's pay tied to the deal. Emerging growth companies and foreign private issuers are exempt.Source 4
Intent to tender
Item 4. Whether the target and its directors, executive officers and affiliates intend to tender, sell or hold their shares, as far as the target knows.Source 4
Appraisal rights
Usually in Item 8, next to lawsuits and approvals. For a Delaware merger under Section 251(h), the statement can serve as the formal appraisal notice.Source 5

On EDGAR, the statement is among the target's filings.

A real example

Gilead's offer for CymaBay, at $32.50 a share, started on February 23, 2024. CymaBay filed its Schedule 14D-9 the same day.Source 6Source 7

It had already filed messages about the deal as SC14D9C, on February 12 and 16, 2024.Source 7

CymaBay's board recommended that holders tender. The vote was unanimous, apart from one director who stepped aside.Source 6

The background section shows the price rising from $23.00 to $32.50. Gilead first proposed $23.00 a share on November 20, 2023.Source 6

On January 25, 2024, it offered $31.00 plus a CVR that could pay up to $2.50 more. On January 30, it offered $32.50, calling it best and final.Source 6

Two financial advisors each gave the board an opinion, dated February 11, 2024, that $32.50 was fair to holders from a financial point of view.Source 6

The filing said the directors and executive officers intended to tender their own shares. The golden parachute table estimated about $38.1 million for the chief executive, mostly from equity awards.Source 6

CymaBay amended the statement six times. On March 15, 2024, after holders sued over its disclosure, it added detail on its projections and advisors' analyses.Source 7Source 8

The last amendment, on March 22, 2024, reported the result. About 77.3% of the outstanding shares had been tendered and not withdrawn.Source 9

What it means for shareholders

The recommendation doesn't bind anyone: each holder still decides whether to tender. Shares not tendered usually get the same cash in the merger that follows, if it closes.

In a hostile offer, the board can recommend rejecting it. If the board changes its recommendation later, the target amends the statement.

Some of the insiders' payments it lists depend on later events, such as losing their job.

The statement can be the Delaware appraisal notice. If it is, a written demand is due by the later of the offer's completion and 20 days after the notice.Source 5

On Tracking Alpha

Tracking Alpha's deal list and deal pages aren't open to the public yet. Once they open, they'll work as described here.

On a deal page, a fact read from the target's statement names the form, SC 14D9, on its source label. The label links to the filing at its page. The deal page lists every filing under Filings.

Easily confused with

Schedule TO
The buyer's filing. The Schedule 14D-9 is the target's answer to it.
Merger proxy statement
The target's document when holders vote on a merger. A Schedule 14D-9 comes with a tender offer, where each holder chooses whether to sell.

Questions

Can a board stay neutral on a tender offer?

Yes. The board can recommend accepting or rejecting the offer, express no opinion and stay neutral, or say it can't take a position. Whichever it chooses, it must give its reasons.Source 2

What is an SC14D9C filing?

A written message about a tender offer that hasn't started yet. It usually comes from the target. Examples are a press release or a letter to employees. It's filed under cover of Schedule 14D-9 no later than the day it's used.Source 1

Sources

  1. 1Law or rule: 17 CFR 240.14d-9, Recommendation or solicitation by the subject company and others (Exchange Act Rule 14d-9), Cornell Legal Information Institute (opens in a new tab)
  2. 2Law or rule: 17 CFR 240.14e-2, Position of subject company with respect to a tender offer (Exchange Act Rule 14e-2), Cornell Legal Information Institute (opens in a new tab)
  3. 3Regulator: US Securities and Exchange Commission, Division of Corporation Finance, Exemptive Order for Tender Offers for Equity Securities (April 16, 2026) (opens in a new tab)
  4. 4Law or rule: 17 CFR 240.14d-101, Schedule 14D-9, with Regulation M-A Items 1005(d), 1011(b) and 1012(a) to (c) (17 CFR 229.1005, 229.1011 and 229.1012) that it calls for, Cornell Legal Information Institute (opens in a new tab)
  5. 5Law or rule: Delaware General Corporation Law, Title 8, Chapter 1, Subchapter IX, Sections 251(c), 251(d), 251(h), 253 and 262, Delaware Code Online (opens in a new tab)
  6. 6Company filing: CymaBay Therapeutics, Solicitation/Recommendation Statement on Schedule 14D-9 on Gilead's tender offer (February 23, 2024) (opens in a new tab)
  7. 7Company filing: CymaBay Therapeutics, EDGAR filing index: Schedule 14D-9, its amendments and SC14D9C filings (February 12 to March 22, 2024) (opens in a new tab)
  8. 8Company filing: CymaBay Therapeutics, Amendment No. 4 to the Schedule 14D-9, Form SC 14D9/A (March 15, 2024) (opens in a new tab)
  9. 9Company filing: CymaBay Therapeutics, Amendment No. 6 to the Schedule 14D-9, Form SC 14D9/A (March 22, 2024) (opens in a new tab)

Tracking AlphaBy Jera Value · Reviewed

Was this page useful?

Join the waitlist and stop checking EDGAR.

How many special situations do you hold right now? Optional